chitosan has been researched along with Parkinson Disease in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (10.53) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 11 (57.89) | 24.3611 |
| 2020's | 6 (31.58) | 2.80 |
| Authors | Studies |
|---|---|
| Dalvi, AV; Ravi, PR; Uppuluri, CT | 1 |
| Lu, J; Qu, Y; Wang, B; Wang, L; Xia, W | 1 |
| Bonifacio, MA; Cometa, S; Dazzi, L; De Giglio, E; Di Gioia, S; Trapani, A; Trapani, G | 1 |
| Ahlawat, J; Deemer, E; Narayan, M; Neupane, R; Sreenivasan, ST | 1 |
| Ali, J; Baboota, S; Iqubal, A; Khan, SA; Nabi, B; Nehal, N; Parvez, S; Pathak, A; Rehman, S; Yar, MS | 1 |
| Choudhury, SR; Karmakar, S; Sardoiwala, MN | 1 |
| Guo, B; Liang, X; Ma, PX; Ren, Y; Zhao, X | 1 |
| Gaud, R; Raj, R; Sridhar, V; Wairkar, S | 1 |
| Rukmangathen, R; Yalavarthi, PR; Yallamalli, IM | 1 |
| Bajaj, A; Gaud, R; Sridhar, V; Wairkar, S | 1 |
| Ali, J; Baboota, S; Fazil, M; Haque, S; Kumar, M; Md, S; Sahni, JK | 1 |
| Ali, A; Ali, J; Baboota, S; Fazil, M; Hasan, Q; Md, S; Mittal, D | 1 |
| Ali, J; Ali, M; Baboota, S; Bhatnagar, A; Jafarieh, O; Kumari, B; Md, S; Sahni, JK | 1 |
| Cao, X; Hou, D; Li, S; Ping, Q; Sun, S; Wang, L; Xu, Y | 1 |
| Cafagna, D; Cometa, S; De Giglio, E; Sabbatini, L; Trapani, A | 1 |
| Agrimi, G; Cafagna, D; Cassano, T; Cuomo, V; De Giglio, E; Denora, N; Gaetani, S; Trapani, A; Trapani, G | 1 |
| Ali, J; Baboota, S; Chuttani, K; Khan, RA; Md, S; Mustafa, G; Sahni, JK | 1 |
| Hazlett, T; Li, RH; White, M; Williams, S | 1 |
| Li, RH; Rein, D; White, M; Williams, S | 1 |
19 other study(ies) available for chitosan and Parkinson Disease
| Article | Year |
|---|---|
Design and evaluation of thermo-responsive nasal in situ gelling system dispersed with piribedil loaded lecithin-chitosan hybrid nanoparticles for improved brain availability.
Topics: Administration, Intranasal; Biological Availability; Biological Transport; Brain; Chitosan; Drug Compounding; Drug Delivery Systems; Drug Design; Drug Stability; Gels; Lecithins; Methylcellulose; Mucociliary Clearance; Nanoparticles; Nasal Mucosa; Parkinson Disease; Particle Size; Piribedil | 2021 |
Chitosan oligosaccharides exert neuroprotective effects
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Chitosan; Disease Models, Animal; Humans; Mice; Mice, Inbred C57BL; Neuroprotective Agents; Parkinson Disease; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt | 2022 |
In vitro investigations on dopamine loaded Solid Lipid Nanoparticles.
Topics: Administration, Intranasal; Antiparkinson Agents; Chitosan; Dopamine; Drug Carriers; Drug Compounding; Drug Liberation; Drug Stability; Fats; Humans; Nanoparticles; Oils; Parkinson Disease; Spectroscopy, Fourier Transform Infrared; Thermogravimetry | 2020 |
Chitosan-Ellagic Acid Nanohybrid for Mitigating Rotenone-induced Oxidative Stress.
Topics: Antioxidants; Apoptosis; Cell Line; Chitosan; Ellagic Acid; Humans; Nanoparticles; Oxidative Stress; Parkinson Disease; Rotenone | 2020 |
Chitosan coated synergistically engineered nanoemulsion of Ropinirole and nigella oil in the management of Parkinson's disease: Formulation perspective and In vitro and In vivo assessment.
Topics: Animals; Benzoquinones; Chitosan; Disease Models, Animal; Drug Stability; Drug Synergism; Emulsions; Female; Humans; Indoles; Male; Molecular Docking Simulation; Nanoparticles; NF-kappa B; Nigella; Oxidopamine; Parkinson Disease; Plant Oils; Rats; Tumor Necrosis Factor-alpha | 2021 |
Chitosan nanocarrier for FTY720 enhanced delivery retards Parkinson's disease via PP2A-EzH2 signaling in vitro and ex vivo.
Topics: alpha-Synuclein; Animals; Biological Availability; Cell Line, Tumor; Chitosan; Disease Models, Animal; Drug Carriers; Enhancer of Zeste Homolog 2 Protein; Epigenesis, Genetic; Fingolimod Hydrochloride; Humans; Mice; Mice, Inbred BALB C; Neurons; Neuroprotective Agents; Parkinson Disease; Phosphorylation; Protein Aggregates; Protein Phosphatase 2; Proteolysis; Signal Transduction; Sphingosine 1 Phosphate Receptor Modulators; Ubiquitination | 2021 |
Injectable hydrogel based on quaternized chitosan, gelatin and dopamine as localized drug delivery system to treat Parkinson's disease.
Topics: Cell Line; Chitosan; Dopamine; Drug Carriers; Drug Liberation; Gelatin; Hydrogels; Injections; Materials Testing; Parkinson Disease; Porosity | 2017 |
Pramipexole dihydrochloride loaded chitosan nanoparticles for nose to brain delivery: Development, characterization and in vivo anti-Parkinson activity.
Topics: Administration, Intranasal; Animals; Antiparkinson Agents; Benzothiazoles; Biomarkers; Blood-Brain Barrier; Chitosan; Disease Models, Animal; Dopamine; Drug Carriers; Drug Delivery Systems; Locomotion; Male; Nanoparticles; Parkinson Disease; Particle Size; Pramipexole; Rats; Reactive Oxygen Species; Tissue Distribution | 2018 |
Biopharmaceutical Potential of Selegiline Loaded Chitosan Nanoparticles in the Management of Parkinson's Disease.
Topics: Administration, Intranasal; Animals; Antiparkinson Agents; Brain; Catalase; Catalepsy; Chitosan; Chlorpromazine; Female; Glutathione; Male; Nanoparticles; Nitrites; Parkinson Disease; Rats, Wistar; Selegiline; Thiobarbituric Acid Reactive Substances | 2019 |
Pharmacokinetics and pharmacodynamics of intranasally administered selegiline nanoparticles with improved brain delivery in Parkinson's disease.
Topics: Administration, Intranasal; Animals; Antiparkinson Agents; Behavior, Animal; Biological Availability; Brain; Chitosan; Disease Models, Animal; Drug Carriers; Drug Liberation; Male; Nanoparticles; Parkinson Disease; Rats; Rats, Sprague-Dawley; Selegiline; Tissue Distribution | 2018 |
Optimised nanoformulation of bromocriptine for direct nose-to-brain delivery: biodistribution, pharmacokinetic and dopamine estimation by ultra-HPLC/mass spectrometry method.
Topics: Administration, Intranasal; Animals; Antiparkinson Agents; Biological Availability; Biological Transport; Blood-Brain Barrier; Brain; Bromocriptine; Chitosan; Chromatography, High Pressure Liquid; Disease Models, Animal; Dopamine; Drug Delivery Systems; Female; Male; Mass Spectrometry; Mice; Nanoparticles; Nasal Mucosa; Parkinson Disease; Radiopharmaceuticals; Sodium Pertechnetate Tc 99m; Tissue Distribution | 2014 |
Brain targeted nanoparticulate drug delivery system of rasagiline via intranasal route.
Topics: Administration, Intranasal; Animals; Biological Availability; Brain; Chemistry, Pharmaceutical; Chitosan; Drug Compounding; Drug Delivery Systems; Goats; Indans; Male; Mice; Nanoparticles; Nasal Mucosa; Neuroprotective Agents; Parkinson Disease; Tissue Distribution | 2016 |
Design, characterization, and evaluation of intranasal delivery of ropinirole-loaded mucoadhesive nanoparticles for brain targeting.
Topics: Adhesiveness; Administration, Intranasal; Animals; Antiparkinson Agents; Brain; Chitosan; Dose-Response Relationship, Drug; Drug Carriers; Drug Liberation; Indoles; Male; Nanoparticles; Parkinson Disease; Particle Size; Radionuclide Imaging; Rats; Surface Properties; Swine; Technology, Pharmaceutical | 2015 |
Effects and molecular mechanism of chitosan-coated levodopa nanoliposomes on behavior of dyskinesia rats.
Topics: Animals; Biocompatible Materials; Blotting, Western; Chitosan; Corpus Striatum; Dopamine Agents; Dopamine and cAMP-Regulated Phosphoprotein 32; Dyskinesia, Drug-Induced; Extracellular Signal-Regulated MAP Kinases; Immunohistochemistry; Levodopa; Liposomes; Male; MAP Kinase Signaling System; Nanoparticles; Parkinson Disease; Phosphorylation; Proto-Oncogene Proteins c-fos; Random Allocation; Rats, Sprague-Dawley; Reproducibility of Results; Treatment Outcome | 2016 |
Dopamine-loaded chitosan nanoparticles: formulation and analytical characterization.
Topics: Chitosan; Dopamine; Humans; Nanoparticles; Parkinson Disease; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; X-Rays | 2011 |
Characterization and evaluation of chitosan nanoparticles for dopamine brain delivery.
Topics: Animals; Biological Transport; Brain; Cell Line; Chitosan; Dogs; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Drug Carriers; Drug Delivery Systems; Male; Microdialysis; Nanoparticles; Parkinson Disease; Photoelectron Spectroscopy; Rats; Rats, Wistar; Reactive Oxygen Species; Tissue Distribution | 2011 |
Bromocriptine loaded chitosan nanoparticles intended for direct nose to brain delivery: pharmacodynamic, pharmacokinetic and scintigraphy study in mice model.
Topics: Administration, Intranasal; Animals; Antiparkinson Agents; Behavior, Animal; Blood-Brain Barrier; Brain; Bromocriptine; Catalepsy; Chitosan; Disease Models, Animal; Drug Compounding; Drug Delivery Systems; Hypokinesia; Injections, Intravenous; Male; Mice; Nanoparticles; Neurons; Parkinson Disease; Radionuclide Imaging; Random Allocation; Sodium Pertechnetate Tc 99m; Tissue Distribution | 2013 |
Poly(vinyl alcohol) synthetic polymer foams as scaffolds for cell encapsulation.
Topics: Animals; Cell Division; Cell Survival; Cell Transplantation; Cells, Cultured; Chitin; Chitosan; Corpus Striatum; Dopamine; Levodopa; Membranes, Artificial; Parkinson Disease; PC12 Cells; Polyvinyl Alcohol; Porosity; Rats; Rats, Sprague-Dawley | 1998 |
Dose control with cell lines used for encapsulated cell therapy.
Topics: Animals; Cell Division; Cell Transplantation; Chitin; Chitosan; Ciliary Neurotrophic Factor; Corpus Striatum; Diffusion Chambers, Culture; Dihydroxyphenylalanine; Dopamine; Feasibility Studies; Hydrogels; Mice; Microspheres; Muscle, Skeletal; Parkinson Disease; PC12 Cells; Prostheses and Implants; Rats; Rats, Sprague-Dawley; Transplantation, Heterotopic | 1999 |